Establishing such a longitudinal relationship is critical to be able to use CSF and blood-based measures of NfL to monitor disease progression and to potentially use NfL as a marker of response to disease intervention in clinical trials for AD as well as other neurodegenerative disorders. This evidence concerns the gene NEFL and Alzheimer disease.